mRNA-Based Therapeutics Beyond Vaccines: Emerging Applications, Challenges, and Future Perspectives

Messenger RNA has progressed from a basic biological messenger into one of the most adaptable therapeutic platforms in modernmedicine . In its native role, mRNA transmits genetic information from DNA to ribosomes, where proteins are synthesized; in

therapeutic applications, that same process is repurposed by delivering engineered mRNA so cells can produce a clinically usefulprotein or functional biomolecule (1-2)This shift has changed the logic of drug development, because the treatment is no longernecessarily the protein itself, but the programmable instruction for making it inside the patient’s own cells (2).The global success of mRNA vaccines during the COVID-19 pandemic marked a decisive turning point for the field . It showed thatsynthetic mRNA could be manufactured rapidly at scale, packaged into effective delivery systems, and produce strong biologicalresponses with acceptable safety in humans (3-4). That achievement validated decades of RNA research and opened the door fornon-vaccine uses in oncology, rare and inherited disorders, protein replacement, cardiovascular disease, autoimmune disease, andegenerative medicine (5-6).One of the greatest strengths of mRNA therapeutics is their versatility . The same platform can be adapted by changing the encoded

sequence, refining untranslated regions, introducing nucleoside modifications, or selecting a different carrier system, making itsuitable for highly individualized interventions.(7-2). This flexibility is especially important for precision medicine, where the idealtherapy may depend on a patient’s tumor profile, mutation type, tissue target, or immune state (8-5).At the same time, the field still faces major translational barriers . mRNA is inherently unstable, can provoke unwanted immunesensing, and remains difficult to deliver efficiently to specific tissues while maintaining durable expression(9-5) . These limitationshave driven intense work in LNP engineering, sequence optimization, and next-generation RNA formats such as self-amplifying RNAand circular RNA . Taken together, the strengths and limitations of mRNA make it one of the most dynamic areas in drug discoveryand a central platform for future therapeutic innovation(10-11).

Figure 1.}Structure of mRNA therapeutics:

1.Biology of mRNA:

mRNA is the intermediary molecule that links genomic information with protein synthesis. In its therapeutic form, mRNA issynthetically produced and optimized to behave as an efficient template for translation while avoiding excessive innate immuneactivation. A therapeutic mRNA molecule typically contains five major elements: a 5′ cap, a 5′ untranslated region, a codingsequence, a 3′ untranslated region, and a poly(A) tail. Each component contributes to stability, translational efficiency, and overallbiological performance (5,6,12).The 5′ cap is critical for ribosome recognition and transcript protection. The untranslated regions influence translation initiation,mRNA stability, and intracellular handling. The coding sequence determines the therapeutic protein to be produced, while the poly(A)tail helps prolong transcript persistence and boost translation. In many therapeutic constructs, nucleoside modifications areintroduced to improve stability and reduce immune sensing. These design features are central to the success of modern mRNAmedicines (7,2,5).

Compared with DNA-based approaches, mRNA offers an important safety advantage because it does not need to enter the nucleusand does not integrate into the genome. This makes it particularly attractive for applications where transient protein expression issufficient or even preferred. For example, temporary expression is ideal in cancer immunotherapy and gene editing, where prolongedactivity could increase toxicity or off-target effects (1,2,6).

2.Components of mRNA Therapeutics:

The therapeutic behavior of mRNA is determined not only by the encoded protein, but also by the molecular architecture of the

transcript. The 5′ cap promotes efficient translation and protects against degradation.

The 5′ and 3′ untranslated regions are powerful regulators of expression. These regions can be borrowed from naturally stabletranscripts or engineered synthetically to enhance ribosome loading and increase mRNA half-life. The coding sequence itself is oftenoptimized for codon usage, reduced secondary structure, and improved protein output. In addition, the poly(A) tail contributes to

translation efficiency and transcript stability (5,12,6).Nucleoside modifications represent one of the most important advances in mRNA engineering. Early synthetic mRNA platformstriggered strong innate immune responses that limited their utility. By incorporating modified nucleotides, researchers can reducectivation of immune sensors while improving translation. This strategy has played a major role in transforming mRNA from anexperimental tool into a clinically viable platform (7,2,9).

Delivery Systems:

Delivery remains the central bottleneck in mRNA therapeutics. Free mRNA is rapidly degraded by nucleases and poorlycrosses cell membranes, so it must be protected by a carrier that enables delivery to the right tissue and supports endosomal escape

after uptake (5,9,13).TABLE:1}Delivery systems for mRNA therapeutics:

Lipid nanoparticles:

Lipid nanoparticles are currently the most advanced and widely used delivery platform for mRNA. They encapsulate andprotect the transcript, improve cellular uptake, and facilitate release into the cytoplasm. Their composition can be tuned with ionizablelipids, cholesterol, phospholipids, and PEG-lipids to optimize stability and reduce toxicity. Because of their success in mRNA

vaccines, LNPs have become the leading platform for therapeutic development beyond vaccines as well (5,13,14).Figure:2-}Lipid nanoparticle-mediated delivery mechanism:

Polymer nanoparticles:

Polymer-based systems are attractive because they can be chemically tailored and may support controlled release. However,their broader clinical use has been limited by cytotoxicity, variable transfection efficiency, an formulation challenges. They remainvaluable in preclinical research and in applications where specialized control over release is needed (9,15).

Liposomes:

Liposomes are biocompatible, flexible carriers that have long been used in drug delivery. They  can encapsulate mRNAeffectively and may be useful for localized delivery or combination therapy. Their clinical translation, however, has been

overshadowed in recent years by the success of optimized LNPs (5,6).

Peptide-based carriers:

Peptides can be designed to enhance cell entry or target specific receptors. These systems are promising for precision

delivery, but they often require significant optimization to balance efficiency, specificity, and safety (5,15).

Viral versus non-viral delivery:

Viral vectors remain highly efficient, but they are associated with concerns about immunogenicity, manufacturing complexity,payload limitations, and repeat dosing. Non-viral systems, particularly LNPs, are increasingly preferred because they are moreflexible and safer for repeated administration. As a result, most next-generation mRNA therapeutics are being developed with

non-viral carriers (5,13).

3.Therapeutic Applications Beyond Vaccines:

Cancer immunotherapy:

Cancer is one of the most promising areas for mRNA therapeutics. mRNA can encode tumor-associated antigens,personalized neoantigens, cytokines, immune-modulating proteins, or receptors used to engineer immune cells. Personalized cancervaccines are especially important because they allow treatment to be tailored to the molecular profile of an individual tumor. This mayimprove specificity and reduce off-target toxicity.mRNA is also useful in ex vivo cell engineering, such as CAR-T cell production or immune cell reprogramming. In these cases,transient expression can be beneficial because it supports functional modification without permanent genetic alteration. Combinationapproaches with checkpoint inhibitors, chemotherapy, or targeted therapy may further enhance effectiveness (6,8,16).

Protein replacement therapy:

Many inherited and acquired diseases result from insufficient production of a functional protein. mRNA offers a direct wayto address this problem by enabling the patient’s own cells to synthesize the missing protein. This has major implications for enzymedeficiencies, metabolic diseases, and disorders involving secreted or intracellular proteins.A key advantage of this strategy is that it bypasses some of the limitations of recombinant protein replacement, such as shorthalf-life, repeated infusions, and high production costs. By using the body as the manufacturing site, mRNA therapies may achievemore physiologic protein distribution (5,12).

Rare genetic diseases:

Rare diseases are particularly attractive targets because many are caused by single-gene defects. mRNA can be used toprovide temporary relacement of a missing protein or, in some cases, to support gene-editing approaches. Since many rarediseases lack effective treatments, mRNA therapeutics may offer a valuable new option.However, these disorders often require delivery to specific organs such as the liver, lung, or central nervous system. This makestargeting a major challenge. Still, the platform’s flexibility and rapid design capabilities make it well suited to orphan diseasedevelopment (6,12).

Cardiovascular diseases:

In cardiovascular medicine, mRNA has been explored for angiogenesis, myocardial repair, and tissue regeneration afterischemic injury. For example, mRNA encoding vascular growth factors may support neovascularization in damaged tissue. Similarly,regenerative proteins could help limit cardiac damage after myocardial infarction.These applications are especially promising because cardiovascular injury often requires short-term signaling rather than permanentprotein expression. Localized delivery may therefore be sufficient to trigger repair processes without prolonged exposure (5,17).

Autoimmune diseases:

Autoimmune diseases may benefit from mRNA-based immune modulation rather than simple suppression. Therapeutic mRNAcould be used to induce tolerance, express immunoregulatory proteins, or alter immune cell behavior. This approach is conceptuallyattractive for diseases such as type 1 diabetes, multiple sclerosis, and rheumatoid arthritis.The goal here is not necessarily high andsustained expression, but controlled expression in the right immune context. This makes mRNA a potentially powerful tool for

immune reprogramming (6,18).

Neurological disorders:

Applications in neurology are more difficult because the blood-brain barrier limits delivery. Nevertheless, mRNA therapies may beuseful for neuroprotective proteins, enzyme replacement, and disease-modifying factors in conditions such as Parkinson’s,

Alzheimer’s, and Huntington’s diseases.

The most important barrier is tissue access. If effective CNS delivery can be achieved, mRNA could become useful for bothreplacement and repair-based strategies (14,5).

Regenerative medicine:

Regenerative medicine may be one of the most conceptually natural uses of mRNA because tissue repair often depends ontransient expression of growth factors and regulatory proteins. mRNA can be used to promote wound healing, bone repair, cartilageregeneration, and stem cell programming.Because regeneration usually requires temporary signaling rather than permanentexpression, mRNA is particularly well suited to this field. It may also work synergistically with biomaterials, scaffolds, and cell therapy

approaches (12,17).

Gene editing:

mRNA is widely used to deliver CRISPR-Cas systems, base editors, and prime editors. In this context, mRNA encodes the editingprotein while guide RNAs direct activity to the target sequence. The transient nature of mRNA expression is a major benefit becauseit reduces the duration of nuclease activity and may lower off-target effects.

This strategy is particularly important for ex vivo editing of cells and for in vivo correction of inherited disorders. Nonetheless, efficient

and specific delivery remains a major barrier (19,20)

Table:2-} Clinical applications beyond vaccines:

4. Clinical Progress:

Clinical translation of mRNA therapeutics is advancing quickly, although the field remains unevenly distributed across indications.

Oncology currently leads in non-vaccine development, especially with personalized cancer vaccines and immune-cell engineering.Rare disease programs are also expanding, particularly in protein replacement and genome editing (5,6,16).The clinical success of mRNA vaccines established regulatory confidence in the platform, which has helped non-vaccine programsmove forward. Several candidates are now in early- and mid-stage trials, and some personalized therapies are showing encouragingsignals. Combination therapy is becoming a major strategy, especially in cancer, where mRNA-based agents are likely to be used

alongside checkpoint blockade or other immunotherapies (5,6,8,21).

5.Artificial Intelligence in mRNA Drug Development:

Artificial intelligence is becoming increasingly important in mRNA research and development. AI can improve sequence design byidentifying optimal codons, untranslated regions, and structural motifs that enhance translation and reduce immune activation. It canalso help predict which delivery systems are most likely to work for particular tissues or disease settings.In oncology, AI can support neoantigen prediction and treatment personalization (22,23,5).

6.Advantages of mRNA Therapeutics:

mRNA therapeutics offer several major advantages. They can be designed rapidly once a disease target is known, making them wellsuited for urgent or personalized applications. They do not integrate into the genome, which improves safety relative to manyDNA-based approaches.(5,6,24).Another advantage is the transient nature of expression. This is useful when short-term protein production is enough to achieve atherapeutic effect, such as in cancer, gene editing, or acute tissue repair. Manufacturing is also relatively flexible, since the sameplatform can often be adapted to different sequences with limited changes in process design (1,5,6,12).

7.Challenges and Limitations:

Despite its promise, mRNA therapeutics face several unresolved challenges. One of the most important is instability, as mRNA iseasily degraded by nucleases and requires careful handling. Delivery is another major obstacle because the molecule must beprotected, internalized by the correct cells, and released into the cytoplasm efficiently(5,13,14).Immunogenicity remains a double-edged sword. Some immune activation can be desirable in vaccines and cancer immunotherapy,but it is often harmful in replacement therapy or gene editing (5,7,24).Manufacturing costs, cold-chain requirements, and stringentquality control also limit accessibility. Regulatory challenges are especially significant for personalized therapies, where each productmay need to be manufactured individually (6,12).These barriers do not diminish the potential of the platform, but they do explain why broad clinical adoption will depend on continuedengineering improvements and translational innovation (16,6).

Table:3-}Advantages and limitations of different delivery platforms:

8. FUTURE PERSPECTIVES:

The future of mRNA therapeutics is expected to move well beyond the first wave of vaccine success and into a more mature era ofprecision, durability, and disease-specific design. As the field evolves, the central challenge will no longer be whether mRNA canwork in humans, but how its performance can be optimized for different tissues, disease mechanisms, and clinical settings. This

transition will likely be driven by innovations in RNA chemistry, delivery engineering, computational design, and manufacturing

science.Self-amplifying mRNA represents one of the most promising next-generation formats. By encoding replication machinery along with

the therapeutic sequence, saRNA can generate more copies of the target transcript inside cells, thereby reducing the dose required

for biological activity. This lower-dose requirement may improve cost-effectiveness, reduce raw material demand, and potentially

enhance immune or therapeutic responses. At the same time, the increased complexity of saRNA design and the need to controlintracellular amplification will require careful safety evaluation, especially for repeated dosing and non-vaccine applications.Circular RNA is another important frontier. Unlike linear mRNA, circRNA lacks free ends, which can make it more resistant toexonuclease degradation and may extend intracellular persistence. This property is especially attractive for applications that require

longer protein expression without continuous re-administration. CircRNA may therefore be useful in protein replacement therapy,regenerative medicine, and chronic disease management. However, the field still needs standardized methods for efficient

circularization, purification, and translation enhancement before circRNA can become broadly clinically useful.Organ-targeted delivery will likely define the next major phase of translation. Current mRNA platforms are highly effective in the liverand certain immune contexts, but many clinically important diseases involve organs that remain difficult to reach, such as the lung,heart, brain, and skeletal muscle. Future delivery systems will need to combine tissue specificity with minimal toxicity and strongendosomal escape. In this setting, ligand-directed nanoparticles, local administration routes, biomaterial-assisted release systems,and organ-selective lipid formulations may all play a role. Improved targeting would not only increase therapeutic efficacy but also

reduce off-target exposure and lower the risk of adverse effects.AI-assisted design is expected to become increasingly central to mRNA drug development. Computational tools can help optimizecodon usage, untranslated regions, secondary structure, and immune-evasion features, while also predicting which delivery systemsare most likely to succeed for a given indication. In oncology, AI may improve neoantigen selection and help generate individualizedtherapeutic constructs more efficiently. In rare diseases, it may support rapid matching of genotype to treatment design. More

broadly, AI may shorten the design-test cycle, reduce development costs, and accelerate movement from concept to clinic.Precision medicine will remain a defining theme of future mRNA therapeutics. Because mRNA can be rapidly customized, it isespecially suited to patient-specific treatment strategies in oncology, inherited metabolic disorders, and immune-mediateddiseases.Global accessibility will also shape the future of the field. Although mRNA medicines have demonstrated remarkable

success, their broader use depends on solutions to cold-chain storage, manufacturing scalability, cost of goods, and regulatorystandardization. If more thermostable formulations, lyophilized products, and decentralized manufacturing approaches becomefeasible, access could expand substantially across low- and middle-resource settings. This would be especially important fortherapeutic applications outside oncology, where long-term treatment cost and infrastructure requirements can be majorbarriers.Overall, the next decade is likely to transform mRNA therapeutics from a highly promising platform into a more diversifiedand clinically integrated technology. The most successful programs will probably be those that combine molecular optimization,targeted delivery, and computational design with a clear understanding of disease biology. As these capabilities mature, mRNA maybecome a foundational component of future medicine, enabling safer, faster, and more personalized therapies across a wide range of

conditions .

Table:4-}. Recent studies on mRNA therapeutics, 2022–2026:

CONCLUSION

mRNA therapeutics have rapidly evolved from a platform best known for vaccines into a broad and highly adaptable class ofmedicines with potential across oncology, rare and inherited diseases, protein replacement, regenerative medicine, autoimmunedisorders, and gene editing. Their appeal lies in a rare combination of features: they can be designed quickly, modified with relativeease, and used to produce proteins transiently without altering the genome. This makes them especially well suited for precision

medicine, where treatment can be matched to disease biology, patient mutation profiles, or individualized immune responses.A major reason for the growing enthusiasm around mRNA is its platform nature. Unlike many traditional drugs that are limited to asingle mechanism or target class, mRNA can be reprogrammed simply by changing the encoded sequence or optimizing the

untranslated regions and delivery vehicle. This flexibility enables rapid adaptation across multiple indications and supports bothstandardized and personalized treatment strategies. In oncology, for example, mRNA can be used to stimulate anti-tumor immunityor engineer immune cells; in genetic disorders, it can restore missing protein function; and in regenerative medicine, it can provideshort-lived biological signals that promote repair and healing.Despite this promise, several important barriers still limit widespread clinical deployment. Delivery remains one of the most difficultproblems, especially for tissues such as the brain, heart, lung, and skeletal muscle. mRNA instability, susceptibility to degradation,and the need for specialized formulations continue to shape manufacturing and storage requirements. In addition, innate immuneactivation, variable expression duration, and the cost of production present major hurdles for long-term and global use. Forpersonalized therapies, regulatory complexity and quality-control demands add another layer of difficulty.The next phase of progress will depend on how effectively the field solves these problems. Advances in lipid nanoparticleengineering, polymer and peptide carriers, organ-targeted systems, and local delivery approaches are expected to improve precisionand reduce toxicity. At the same time, innovations in molecular design, including nucleoside modification, self-amplifying RNA, andircular RNA, may enhance stability and extend expression. AI-assisted optimization is also likely to accelerate sequence design,

target selection, and delivery strategy development, making therapeutic development faster and more predictive.Overall, mRNA therapeutics are moving toward a future in which they serve as a foundational tool in modern biomedicine rather than

a niche technology. Their ability to bridge basic biology, precision medicine, and translational therapy gives them exceptionallong-term potential. If ongoing scientific, manufacturing, and regulatory challenges can be addressed, mRNA medicines may becomean increasingly routine part of clinical practice across a wide range of diseases.

REFERENCES

1. Sahin U, Karikó K, Türeci Ö. mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery.2014;13(10):759–780.
2. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery.2018;17(4):261–279.
3. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New England Journal of Medicine. 2020;383(27):2603–2615.
4. 4.Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. New England Journal ofMedicine. 2021;384(5):403–416.
5. Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Materials. 2021;6:1078–1094.
6. Verbeke R, Lentacker I, De Smedt SC, Dewitte H. Three decades of messenger RNA vaccine development. Nature Reviews DrugDiscovery. 2021;20(6):429–450.
7. Karikó K, Muramatsu H, Welsh FA, et al. Incorporation of pseudouridine into mRNA yields superior non-immunogenic vectors withincreased translational capacity and biological stability. Molecular Therapy. 2008;16(11):1833–1840.
8. Sahin U, Derhovanessian E, Miller M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunityagainst cancer. Nature. 2017;547:222–226.
9. Kowalski PS, Rudra A, Miao L, Anderson DG. Delivering the messenger: advances in technologies for therapeutic mRNA delivery.Molecular Therapy. 2019;27(4):710–728.
10. Blakney AK, McKay PF, Shattock RJ. Structural components for the optimization of mRNA vaccines. Frontiers in MolecularBiosciences. 2021;8:660302.
11. Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells.Nature Communications. 2018;9:2629.
12. Damase TR, Sukhovershin R, Boada C, et al. The limitless future of RNA therapeutics. Frontiers in Bioengineering andBiotechnology. 2021;9:628137.
13. Mitchell MJ, Billingsley MM, Haley RM, et al. Engineering precision nanoparticles for drug delivery. Nature Reviews Drug

Discovery. 2021;20:101–124.

14. Eygeris Y, Patel S, Jozic A, Sahay G. Deconvoluting lipid nanoparticle structure for mRNA delivery. Nano Letters.2022;22:576–589.
15. Ramishetti S, et al. Polymeric nanoparticles for RNA delivery. Nature Reviews Materials. 2021.PubMed Central (PMC).
16. Liu MA. mRNA therapeutics for cancer and beyond. Nature Reviews Clinical Oncology. 2023.
17. Zangi L, Lui KO, von Gise A, et al. Modified mRNA directs the fate of the heart. Nature Biotechnology. 2013;31:898–907.
18. Qin S, et al. mRNA therapeutics for autoimmune diseases: current advances and future perspectives. Signal Transduction andTargeted Therapy. 2023.
19. Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. New England Journal ofMedicine. 2021;385:493–502.
20. Musunuru K, Chadwick AC, Mizoguchi T, et al. In vivo CRISPR base editing of PCSK9. Nature. 2021;593:429–434.
21. Ott PA, Hu Z, Keskin DB, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature.2020;547:217–221.
22. Yang Y, et al. Artificial intelligence for RNA therapeutic design and development. Nature Machine Intelligence. 2024.
23. Gupta R, et al. AI-enabled optimization of mRNA therapeutics: current advances and future perspectives. Briefings inBioinformatics. 2023.
24. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery.2018;17(4):261–279.
25. Patil Y, et al. Advances in mRNA non-viral delivery approaches. Advanced Drug Delivery Reviews. 2021.
26. Molecular mechanisms, delivery platforms, regulatory frameworks, and equitable global access of mRNA therapeutics (2026,Advanced Drug Delivery Reviews)
27. Arral ML, Whitehead KA. Design principles of lipid nanoparticles for RNA delivery. Nature Reviews Bioengineering. 2026.
28. Nature Reviews Drug Discovery article: Lipid nanoparticles for mRNA deliveryHou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature Reviews Drug Discovery. 2021;20:731–750.DOI: 10.1038/s41573-021-00224-5.